Emergent Biosolutions (EBS) Tops Q2 EPS by 6c, Posts FY11 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.23 +0.48%
EPS Growth %: -138.7%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
ORPB, PBCO, SICP, More
EPS Growth %: -138.7%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q2 EPS of $0.40, $0.06 better than the analyst estimate of $0.34. Revenue for the quarter came in at $88.1 million versus the consensus estimate of $84.2 million.
Emergent Biosolutions sees FY2011 net income of $15 to $25 million. Emergent Biosolutions sees FY2011 revenue of $270-$290 million, versus the consensus of $326.68 million.
Emergent Biosolutions sees FY2011 net income of $15 to $25 million. Emergent Biosolutions sees FY2011 revenue of $270-$290 million, versus the consensus of $326.68 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Knowles (KN) Tops Q3 EPS by 2c; offers guidance
- CVB Financial (CVBF) Tops Q3 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
